MDM2 Inhibitor Nutlin-3a Induces Apoptosis and Senescence in Cutaneous T-Cell Lymphoma: Role of p53  by Manfé, Valentina et al.
MDM2 Inhibitor Nutlin-3a Induces Apoptosis
and Senescence in Cutaneous T-Cell Lymphoma:
Role of p53
Valentina Manfe´1, Edyta Biskup1, Peter Johansen2, Maria R. Kamstrup1, Thorbjørn F. Krejsgaard3,
Niels Morling2,4, Hans C. Wulf1 and Robert Gniadecki1,4
P53 is rarely mutated in cutaneous T-cell lymphoma (CTCL) and is therefore a promising target for innovative
therapeutic approaches. Nutlin-3a is an inhibitor of MDM2 (human homolog of murine double minute 2), which
disrupts its interaction with p53, leading to the stabilization and activation of p53. To investigate the potential
therapeutic use of nutlin-3a in CTCL, we screened CTCL lines Hut-78, SeAx, MyLa2000, Mac1, and Mac2a by
measuring p53 levels after nutlin-3a treatment. In MyLa2000, Mac1, and Mac2a, we observed the increase in p53,
indicating the fully functional p53. In the remaining cell lines, P53 mutation analysis identified a homozygous
nonsense mutation (R196Stop in Hut-78) and a homozygous missense mutation (G245S in SeAx). In MyLa2000,
Mac1, and Mac2a carrying wild-type P53, nutlin-3a induced apoptosis and senescence demonstrated by
permanent G0/G1 cell-cycle block and expression of the senescence-associated b-galactosidase. This effect was
abolished in cells in which p53 was silenced by small interfering RNA. Se´zary cells lack functional p53 and were
resistant to nutlin-3a. However, nutlin-3a potentiated the efficacy of conventional chemotherapeutics not only
in cells with intact p53 but also in Hut-78, SeAx, and Se´zary cells. Thus, targeting p53 by nutlin-3a may constitute
a therapeutic approach in CTCL because of increased apoptosis and senescence of tumor cells.
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INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group
of T-cell lymphomas, of which mycosis fungoides (MF), Se´zary
syndrome (SS), and CD30þ lymphoproliferative diseases are
the most common types. Whereas MF in the early stage has
a good prognosis, progression into erythroderma and tumors
is associated with aggressive clinical course and shortened
survival (Mao et al., 2002; Willemze et al., 2005; Agar et al.,
2010). Primary cutaneous CD30þ lymphoproliferative dis-
orders comprise B30% of all primary CTCLs and include
lymphomatoid papulosis and primary cutaneous anaplastic
large-cell lymphoma. Advanced CTCL is a therapeutic
challenge. Traditional therapies comprising radiotherapy and
anthracycline- or nucleoside analog–based regimens provide
only short-lived responses (Zinzani et al., 2000; Wollina
et al., 2003). Current research efforts are therefore concen-
trated on a better understanding of chemotherapy resistance
in advanced CTCL and on identification of new pharmaco-
logical targets (Kamstrup et al., 2010a, 2010b; Manfe et al.,
2010).
p53 is a tumor-suppressor protein that is activated in
response to stress signals and restricts cell proliferation by
inducing apoptosis, cell-cycle arrest, or senescence (Vogel-
stein et al., 2000; Harris and Levine, 2005; Vousden and
Prives, 2009; Nardella et al., 2011). However, p53 can also,
paradoxically, contribute to cell survival, suggesting that p53
response depends on the type of tissue, the nature of the stress
signal, and the cellular environment (Vousden and Prives,
2009). p53 serves as a transcriptional activator of numerous
target genes (e.g., BAX, NOXA, PUMA, and p21WAF1CIP1),
but no p53 target gene knockout mouse has been shown
to recapitulate the cancer predisposition of p53-null mice
(Lozano and Zambetti, 2005). Moreover, in some tumor cell
lines, specific inhibition of p53 target gene transcription did
not affect p53-dependent apoptosis (Caelles et al., 1994;
Wickremasinghe et al., 2011). Thus, an alternative p53
pathway may cause cellular responses independent of
de novo gene transcription (Wickremasinghe et al., 2011).
This nontranscriptional mechanism of p53 was described in
leukemia and predominantly involves the core apoptotic
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machinery located on the mitochondria (Steele et al., 2008).
p53 can, through its DNA-binding domain, interact and
neutralize the anti-apoptotic functions of Bcl-2, Bcl-KL with
subsequent activation of pro-apoptotic BH-3 proteins (BAK
and BAX) and induction of mitochondrial permeabilization
and apoptosis (Bossi and Sacchi, 2007; Vaseva et al., 2009;
Wickremasinghe et al., 2011).
As the p53 activation is inhibited by the binding to the E3
ubiquitin ligase, human homolog of the murine double minute
2 (MDM2) (Haupt and Haupt, 2004), a small antagonist of
MDM2, nutlin-3a, has been highlighted as a promising tool
to stabilize and activate p53 (Vassilev et al., 2004; Lau et al.,
2008). In this regard, nutlin-3a has been shown to trigger
apoptosis or senescence in several hematological malignan-
cies including Hodgkin’s lymphomas, mantle cell lympho-
mas, Kaposi’s sarcoma–associated herpesvirus lymphomas,
and anaplastic large-cell lymphomas (Saha et al., 2010), and
to synergize with chemotherapies (Coll-Mulet et al., 2006;
Secchiero et al., 2007, 2009; Barbarotto et al., 2008; Carter
et al., 2008; Kojima et al., 2008; Zhu et al., 2008; Drakos
et al., 2009; Voltan et al., 2010) and radiation (Long et al.,
2010). Recently, it was demonstrated that nutlin-induced
activation of the p53 pathway results in p53-dependent
apoptosis in cells harboring P53 wild type (wt), as well as
mutated (mut) but partially functional P53 (Drakos et al.,
2009). In cells lacking a functional p53, nutlin-3a can instead
induce the activation of other partners of MDM2, including
p73 or E2F1, and trigger apoptosis in a p53-independent
mechanism (Lau et al., 2008).
P53 mutations occur rarely in MF and CD30þ lympho-
proliferative diseases and are not necessarily associated with
disease progression, as demonstrated by recent studies that
found mutation rates of 2% and 5%, respectively (Kapur
et al., 2001, 2005; Dereure et al., 2002). A focal deletion at
17p13.3–17p13.1, leading to the loss of P53, has been
detected in 75–80% of patients with SS (Marrogi et al., 1999;
Vermeer et al., 2008; Steininger et al., 2011). Here we
investigated the potential therapeutic utility of nutlin-3a
either alone or in combination with other pro-apoptotic drugs
in CTCL cell lines and in primary leukemic Se´zary cells. We
showed that nutlin-3a could induce apoptosis and senes-
cence in CTCL cells harboring P53wt, but it was unable to
induce apoptosis in cells with P53mut and in purified primary
Se´zary cells. We demonstrated that nutlin-induced apoptosis
in CTCL cells depends on the presence of a functional p53
and at least in part occurs via a p53 nontranscriptional
mechanism. The p53 transcriptional function limits induction
of apoptosis probably through the transcriptional upregulation
of anti-apoptotic proteins. Finally, we found that nutlin-3a
potentiates the effect of several pro-apoptotic agents includ-
ing g-secretase inhibitor-1, bortezomib, and doxorubicin in
cells with P53wt and P53mut, and in primary leukemic Se´zary
cells.
RESULTS
Expression and mutation status of P53 in CTCL cells
The functionality of the p53 pathway in primary leukemic
cells from SS and in the CTCL cell lines was probed with
nutlin-3a (Figure 1a). Cells with functionally intact p53 are
expected to respond to nutlin-3a with an increase in cellular
p53 content and its downstream target, p21WAF1/CIP1 (Vassi-
lev et al., 2004). As a consequence of focal deletion at
17p13.3–17p13.1 of P53 (Vermeer et al., 2008; Steininger
et al., 2011), Se´zary cells showed no p53 expression (Figure
1a) and lack of a functional p53. Similarly, Hut-78 cells
lacked p53 expression, consistent with a possible deletion
or nonsense mutation. SeAx, MyLa2000, Mac1, and Mac2a
showed an accumulation of p53 and MDM2 proteins after
24 hours of exposure to nutlin-3a. p21 increased as expected
in MyLa2000, Mac1, and Mac2a cells, but not in SeAx,
suggesting that the transcriptional activity of p53 was
impaired in the latter cell line. These findings implied that
p53 is fully functional in MyLa2000, Mac1, and Mac2a, but
not in Hut-78 and SeAx. To further explore these findings, we
sequenced the entire open reading frame of P53 in Hut-78
and SeAx. We verified the previously reported homozygous
nonsense P53 mutation at codon 196 in Hut-78 (R196Stop)
(Ri et al., 2009) and identified a homozygous missense
mutation at codon 245 (G245S) of exon 7 in SeAx cells at the
DNA-binding domain (Table 1). The G245S is a nonfunc-
tional mutation located in the mutational hot spot region
(exons 5–9) of P53 and is observed in several cancers including
hematological malignancies (Hu et al., 1992; Wada et al.,
1993; Kurosawa et al., 1995; Villuendas et al., 1997; Wong
et al., 1999; Leroy et al., 2002; Wojcik et al., 2005). Although
the G245S mutation disrupts the DNA-binding surface, the
overall scaffold is retained when the protein is folded (Wong
et al., 1999), explaining the observed stabilization of p53
after nutlin-3a.
Nutlin-3a promotes apoptosis in P53wt cells independent of the
transcriptional activity of p53
Having established the functionality of p53 in the CTCL cell
lines, we tested the ability of nutlin-3a to induce apoptosis.
As shown in Figure 1b, nutlin-3a potently induced apoptosis
in Mac1 cells, whereas the effect in MyLa2000 and Mac2a
was weaker. The viability of P53mut Hut-78 and SeAx and
Se´zary cells (Figure 1c) was not altered by nutlin-3a, under-
scoring the assumption that nutlin-induced apoptosis is p53
dependent. This is further confirmed by the observation that
the specific attenuation of P53 using small interfering RNA
(siRNA; Figure 1d) abolished nutlin-induced apoptosis in
Mac1 (Figure 1e). The p53 protein accumulation after nutlin-
3a was effectively downregulated in p53 siRNA–transfected
groups compared with the scrambled siRNA–transfected ones
(Figure 1d). We observed no correlation between the different
responses to nutlin-induced apoptosis in CTCL cell lines and
the cytotoxic effect of two pro-apoptotic agents, doxorubicin
and etoposide (Supplementary Figure S1a and b online).
Thus, we suggest that the apoptotic response induced by
doxorubicin or etoposide in CTCL cells is modulated by
factors other than P53 status.
An interesting insight in the role of the transcriptional
versus the nontranscriptional mechanism of p53 action in
apoptosis was gained using a pharmacological inhibitor of the
p53-mediated transcription, pifithrin-a (PFT-a). Preincubation
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with 25mM PFT-a substantially inhibited the nutlin-3a induction
of the p53 transcriptional target, p21, without affecting the
p53 accumulation in Mac1 cells (Figure 2a). PFT-a alone did
not show any apoptotic effect, but increased the cytotoxicity
of nutlin-3a (Figure 2b and c) in Mac1. PFT-a had no effect on
the P53mut cells, SeAx, or Hut-78 (data not shown). These
data indicate that the p53 transcriptional activity is dispen-
sable for apoptosis and may even inhibit the nutlin-induced
apoptosis in CTCL cell lines.
We then investigated whether PFT-a can also affect the
apoptosis induced by doxorubicin and etoposide. PFT-a did
not affect doxorubicin or etoposide cytotoxicity in both P53wt
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Figure 1. Nutlin-3a induced apoptosis through p53 in cutaneous T-cell lymphoma (CTCL) cells with functional p53. (a) Purified leukemic Se´zary cells
and CTCL cells were cultured with or without nutlin-3a, at the indicated doses, for 24 hours, and the expression level of p53-related proteins was detected
using western blot analysis. b-Actin was used as the housekeeping gene, and relative protein expression levels are reported below the corresponding
western blot bands. The immunoblots of Se´zary cell lysates show the results of one representative of three patients. MDM2, human homolog of murine
double minute 2. (b, c) Effects of the 24-hour nutlin-3a treatment on cell viability in (b) P53wt or (c) P53mut CTCL cells and in purified leukemic Se´zary cells.
mut, mutant; wt, wild type. Cell viability was expressed as the percentage of the propidium iodide (PI)-negative cells measured by flow cytometry. Points
indicate mean (n¼ 3) and bars indicate SEM. *P-value o0.05 compared with the untreated control. (d) Efficiency of p53 small interfering RNA (siRNA)
transfection evaluated by western blot analysis. Mac1 cells were transfected for 24 hours with either scrambled (control) or p53 siRNA and treated for
24 hours with nutlin-3a (0 and 5mM). b-Actin was used as the housekeeping gene, and relative protein expression levels are reported below the corresponding
western blot bands. (e) Mac1 cells were transfected for 24 hours with either scrambled (control) or p53 siRNA and treated for additional 24 hours with
nutlin-3a (2.5 mM). Annexin V and PI staining for flow cytometry was performed as described in the Materials and Methods. The dot-plot graphs (annexin V:
green FL1 channel, x-axis; PI: red FL3 channel, y-axis) are representative of three independent experiments.
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and P53mut CTCL cells (Supplementary Figure S1c and d
online), suggesting that the chemotherapeutics-dependent
apoptosis mainly occurs independent of the transcriptional
activity of p53.
Nutlin-3a induces senescence followed by cell-cycle block
Exposure to nutlin induced a complete inhibition of BrdU
incorporation in MyLa2000, Mac1, and Mac2a within
24 hours (Figure 3a). Flow cytometric cell-cycle profiling
further demonstrated an 80% reduction in the percentage
of cells in the S phase, with a concomitant increase in the
G0/G1 population (Figure 3b). Mac1 showed a rapid and
pronounced apoptosis that made analyzing of the cell cycle
difficult. The proliferation of CTCL cells lacking a functional
p53 was essentially unaffected even after a long period of
exposure to nutlin (up to 1 week, data not shown). The arrest
in cell proliferation in Mac2a and Myla2000 was irreversible
as it did not resume even up to 40 hours after nutlin-3a
removal (Figure 3c).
As cellular senescence is the condition commonly
associated with the irreversible G0 cell-cycle arrest, we
performed senescence-associated b-galactosidase (SA-b-gal)
staining to investigate the possible induction of senescence
by nutlin-3a. As shown in Figure 3d, MyLa2000 and Mac2a
cells were clearly SA-b-gal positive after 72 hours of exposure
to nutlin-3a, whereas P53mut cells (SeAx, Hut-78; Figure 3d)
and Se´zary cells (data not shown) remained unstained. PFT-a-
pretreated cells retained the ability to enter cell-cycle block
and senescence after nutlin-3a (Figure 4b and c) even in the
absence of p21, which is a known inducer of senescence.
This effect of PFT-a was not observed in SeAx and Hut-78
cells (data not shown). Thus, p53 induces senescence in
MyLa2000 and Mac2a cells, independently of its transcrip-
tional activation of p21.
Table 1. CTCL cell lines with P53 mutations
Ref Start End Ref Var Total Var Ref Var Region Known Codon
Cell accno pos pos nuc nuc depth freq AA AA name SNPs pos
SeAx chr17 7577548 7577548 C T 81 100% G S P53 245
SeAx chr17 7592168 7592168 C G 92 99% R G WRAP53 rs2287499 68
Hut-78 chr17 7579472 7579472 G C 380 97% P R P53 rs1042522 72
Hut-78 chr17 7578263 7578263 G A 163 100% R Stop P53 196
Abbreviations: AA, amino acid; chr17, chromosome 17; freq, frequency; nuc, nucleotide; Ref accno, accession number of the reference sequence; SNP,
single-nucleotide polymorphism ID; Start or End pos, start or end position within the reference sequence.
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Figure 2. Inhibition of the p53 transcriptional activities by pifithrin-a (PFT-a) increased nutlin-induced apoptosis. (a) The p53 and p21 immunoblots of
Mac1 lysates pretreated with 25mM PFT-a for 4 hours, followed by 5 mM nutlin-3a for additional 20 hours. b-Actin was used as the housekeeping gene, and
relative protein expression is reported as in Figure 1a. (b, c) Increase in apoptotic, annexin V–positive cells in Mac1 cells pretreated with PFT-a and exposed
to nutlin (1.25, 2.5; 24 hours) compared with those not exposed to PFT-a. Flow cytometry was performed as described in Figure 1e. Representative example of
(b) three independent experiments and (c) quantification. Columns indicate mean (n¼ 3) and bars indicate SEM. *P-value o0.05 compared with cells not
exposed to PFT-a.
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Nutlin-3a sensitized P53wt and P53mut CTCL cells to
chemotherapeutic agents
We compared the effect of nutlin-3a on chemotherapy-
induced apoptosis in CTCL cells harboring a functional p53
(MyLa2000) or P53mut (Hut-78). We considered three chemo-
therapeutic agents, bortezomib, doxorubicin, and g-secretase
inhibitor-I (inhibitor of Notch-1), that have previously shown
to be powerful pro-apoptotic agents in CTCL cells (Kamstrup
et al., 2010a, 2010b). As shown in Figure 5, the apoptotic
effect of the three chemotherapeutic agents was significantly
enhanced by nutlin-3a in both MyLa2000 and Hut-78. Impor-
tantly, nutlin-3a potently increases the apoptosis induced by
doxorubicin and bortezomib in primary leukemic Se´zary
cells (Figure 5c). As Hut-78 cells and Se´zary cells lack a
functional p53, we concluded that nutlin-3a enhanced the
effect of chemotherapy in a p53-independent manner. Moreover,
we suggest that other pathways, including the p53-related
proteins p73 and E2F1 (Ambrosini et al., 2007), may com-
pensate for p53 function and thus contribute to the increased
apoptotic effect in P53mut CTCL cells.
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Figure 3. Nutlin-3a induced G0/G1 cell-cycle arrest and senescence in P53wt cutaneous T-cell lymphoma (CTCL) cells. (a, b) Cells were incubated with or
without 5 mM nutlin-3a for 24 hours, and cell-cycle analysis was performed by flow cytometry. (a) Histograms (big panels) show the DNA content. Top right of the
panels show the rate of BrdU incorporation (BrdU vs. 7-aminoactinomycin D (7-AAD)/DNA content). BrdU-negative cells were gated, as shown in the boxed
region. (b) Percentages of the cells in each phase of cell cycle are reported. Representative example of a set of three independent experiments. (c) Nutlin-3a
induced a prolonged cell-cycle arrest. Cells were cultured with or without 10mM nutlin for 48 hours. Cells were then washed and incubated with or without
nutlin-3a (10 mM) for another 48 hours. BrdU incorporation was analyzed by flow cytometry, as described in the Materials and Methods. The percentage of BrdU-
positive cells is reported as representative example of three independent experiments. (d) Microscopic evaluation of cellular senescence by senescence-
associated b-galactosidase (SA-b-gal) staining in cells incubated with or without nutlin-3a (10 mM) for 72 hours. Bar¼ 10mm.
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DISCUSSION
Owing to the central role of p53 in preventing inappropriate
cell proliferation and maintaining genomic integrity follow-
ing genotoxic stress, there is an interest in the development
of pharmacological strategies aimed to manipulate p53 and
maximize the selectivity and efficiency of cancer cell era-
dication. These strategies include gene therapy approaches
that intend to restore de novo p53 expression and com-
pounds, such as nutlin-3a that relies on induction of p53
activity by relieving p53 from the inhibition of MDM2 (Haupt
and Haupt, 2004; Bossi and Sacchi, 2007). In this study, we
provided rationale for the future development of nutlin-3a
for the therapy of CTCL. We showed that nutlin-3a induces
apoptosis and senescence in CTCL cell lines. This effect is
dependent on intact p53 as cells with mutated P53 (Hut-78,
SeAx, and primary leukemic Se´zary cells) did not respond to
nutlin-3a, and downregulation of p53 by siRNA attenuated
the apoptotic effect in cells with P53wt. However, pifithrin-a,
the potent inhibitor of the transcriptional activity of p53,
enhanced, rather than attenuated, apoptosis and did not have
any influence on cell-cycle arrest after nutlin-3a, strongly
indicating that the effect of p53 is transcription independent.
Our data are supported by previous studies that emphasized
the complex relationship between the transcriptional and
nontranscriptional signaling pathways (Steele et al., 2008;
Vaseva et al., 2009). The biological p53 functions may just in
part be related to the p53 transcriptional activity, and
biochemical actions at the mitochondrial outer membrane
can trigger apoptosis in specific settings as tumor suppression
(Brady et al., 2011; Wickremasinghe et al., 2011). The p53
transcriptional functions, instead, can paradoxically result in
a feedback anti-apoptotic response and, thus, reduce the
apoptosis induced by agents that elevate cellular levels of
p53. Thus, identifying a strategy to selectively inhibit some
p53 functions that impair its therapeutic effect would be
valuable for chemotherapy in therapy-resistant CTCL.
It has been suggested that p53-induced senescence is an
important mechanism of tumor regression induced by standard
genotoxic chemotherapy (Roninson et al., 2001, 2003), and
has recently been shown to be a key determinant of tumor
response to nutlin-3a (Efeyan et al., 2007; Hasegawa et al.,
2009; Villalonga-Planells et al., 2011). Although there was
skepticism to the clinical use of pro-senescent therapy, it is
now clear that cellular senescence is a robust physiological
antitumor response and that senescent cells are cleared by
the immune system in vivo (Nardella et al., 2011). Here, we
showed that senescence is a major response to agents that
induce p53 activity in CTCL. Moreover, we considered the
combination of the therapeutic induction of senescence with
already established therapies (e.g., doxorubicin and bortezo-
mib) as a possible implementation in the clinical treatment of
CTCL. p21 is a common senescence-associated effector, and
its persistent expression after nutlin-3a treatment has been
associated with senescence in leukemia (Drakos et al., 2009;
Hasegawa et al., 2009; Shen and Maki, 2010; Nardella et al.,
2011). Surprisingly, we reported that attenuation of p21 by
pifithrin-a enhanced rather than attenuated nutlin-induced
senescence in CTCL cells. Our data are in agreement with
a previous finding that suggested opposing roles of p21
depending on cell type and context (Gartel, 2006). Usually,
p21 functions as a tumor suppressor (Philipp et al., 1999;
Martin-Caballero et al., 2001), but in some cases may display
pro-cancer and anti-apoptotic activities (De la Cueva et al.,
2006).
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Figure 4. The p53 transcriptional activity was dispensable for cellular senescence. (a) The p53 and p21 protein levels were assessed by western blot
analysis in MyLa2000 cells pretreated with 25mM pifithrin-a (PFT-a) for 4 hours, followed by 5 mM nutlin-3a for additional 20 hours. b-Actin was used as
the housekeeping gene, and relative protein expression is reported as in Figure 1a. (b) Cells treated with 25mM PFT-a for 4 hours at the indicated doses of
nutlin-3a (1.25, 2.5, and 5 mM; 20 hours) were analyzed by flow cytometry (BrdU vs. 7-aminoactinomycin D (7-AAD)/DNA content). BrdU-positive cells,
calculated as in Figure 3c, are shown. Columns indicate mean (n¼ 3) and bars indicate SEM. *P-value o0.05 compared with cells not exposed to PFT-a.
(c) Representative photomicrographs of MyLa2000 cells stained with senescence-associated b-galactosidase (SA-b-gal) after 72 hours of treatment with
PFT-a and/or 5 mM nutlin-3a. Bar¼ 10 mm.
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Taking into account the absolute requirement for p53 in
nutlin-induced apoptosis and senescence, the finding that
nutlin-3a enhanced the effects of chemotherapeutics even in
P53mut cells and Se´zary cells was surprising. The exact nutlin-
3a mechanism in P53mut CTCL cell lines remains unknown,
although it has been suggested that other partners of MDM2,
including p73 or E2F1, are capable of compensating for p53
function (Ambrosini et al., 2007). The finding that the
enhancing efficacy of nutlin-3a on chemotherapy-induced
cytotoxicity is preserved in the absence of p53 has con-
sequences for drug development. Preclinical trials combining
nutlin-3a with tumor necrosis factor–related apoptosis-indu-
cing ligand or bortezomib are currently being performed for
leukemia (Hasegawa et al., 2009; Jin et al., 2010). Although
nutlin-3a treatment alone represents a promising therapeutic
treatment for MF and CD30þ lymphoproliferative diseases,
the lack of a functional p53 impairs the nutlin-3a application
in SS. We thus suggest that a nutlin-3a combined treatment
could offer a promising treatment of SS.
MATERIALS AND METHODS
Cell cultures and reagents
Five CTCL cell lines were used: MyLa2000, derived from a plaque
biopsy of a patient with MF (Gootenberg et al., 1981), SeAx (Kaltoft
et al., 1987) and Hut-78 (Gazdar et al., 1980), derived from peri-
pheral blood of patients with SS, and Mac1 and Mac2a, derived from
different clinical specimens of a patient showing progression from
lymphomatoid papulosis to anaplastic large-cell lymphoma (Davis
et al., 1992). Cells were maintained as described (Kamstrup et al.,
2008, 2010b). MyLa2000 and SeAx cells were cultured in Gibco
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Figure 5. Nutlin-3a increased cytotoxicity of pro-apoptotic agents. (a) MyLa2000, (b) Hut-78, or (c) Se´zary cells were pretreated with nutlin (5 or 10 mM)
for 4 hours and then exposed to g-secretase inhibitor-1 (GSI-1; 0.5, 1, and 1.5 mM), bortezomib (2.5, 5, and 7 nM), or doxorubicin (0.2 and 0.4 mM) for 48 hours.
PI, propidium iodide. Cell viability was determined as in Figure 1b. Because the Se´zary cells could not be purified in large quantities, the experiments
were only performed using 10 mM nutlin-3a. Points indicate mean (n¼3) and bars indicate SEM. *P-value o0.05 versus untreated cells.
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GlutaMAX (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum at 37 1C under 5% CO2. Hut-78, Mac2a, and Mac1 cells
were cultured in RPMI-1640 containing 2mM L-glutamine and 10%
fetal bovine serum. Nutlin-3a was obtained from Cayman Chemical
(Ann Arbor, MI), and g-secretase inhibitor-1 (Z-Leu-Leu-Nle-CHO)
from Merck Calbiochem (Darmstadt, Germany). Bortezomib (Z-Leu-
Leu-Leu-CHO) was purchased from Selleck (West Paterson, NJ), and
doxorubicin hydrochloride from Sigma-Aldrich (St Louis, MO).
Isolation of CD7 CD4þ Se´zary cells
Peripheral blood mononuclear cells were isolated, after written
informed consent, from blood of three patients diagnosed with SS,
as described previously (Kamstrup et al., 2010b). CD7 CD4þ cells
were isolated using the Anti-Biotin Multisort Kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) together with an anti-CD7 biotin-
conjugated antibody (eBioscience, San Diego, CA) and anti-CD4
micro beads (Miltenyi Biotec) according to the manufacturer’s
instructions. Se´zary cells were maintained in RPMI-1640 containing
2mM L-glutamine, 10% fetal bovine serum, and 1% penicillin/
streptomycin. The study was approved by the Ethics Committee of
Copenhagen and Frederiksberg and was conducted in accordance
with the Declaration of Helsinki Principles.
Detection of P53 mutation
Genomic DNA was extracted from 5 106 cells using the QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. Elution was performed in 200 ml AE buffer
(Qiagen). The entire open reading frame of the P53 gene was amplified
using Platinum Taq DNA Polymerase High Fidelity (Invitrogen) and a
specific set of primers (Supplementary Table S1 online). The PCR
program included initial DNA denaturation at 94 1C (2minutes),
followed by 35 cycles of 94 1C (20 seconds), 62 1C (20 seconds), and
68 1C (8.5minutes), and finally extension at 68 1C (5minutes). The
PCR products were separated by electrophoresis on a 1.2% FlashGel
DNA cassette (Lonza, Rockland, ME) using the FlashGel system
(Lonza). The remaining PCR product was purified by QiaQuick
(Qiagen) spin columns to remove leftovers from the PCR. Elution
volume was 30 ml of buffer EB (Qiagen). The concentration of each
fragment was determined using a fluorescent DNA–binding dye
(QuantiFlour dsDNA System, Promega, Madison, WI) according to
the manufacturer’s protocol. The fragments were then pooled in
equimolar ratios. The cell line PCR products were sequenced in
multiplex on the GS Junior sequencing platform (454 Sequencing,
Branford, CT). Specific bar-code sequences were ligated onto the
PCR products of each cell line during the library preparation. Sample
preparation and sequencing were done using the manufacturer’s
protocol. The obtained sequences were sorted based on the ligated
bar-code sequence. The sequence of each cell line was mapped
to the DNA sequence of chromosome 17 downloaded from the
University of California, Santa Cruz (UCSC) genome browser (http://
genome.ucsc.edu/) using the GS Reference Mapper software (454
Sequencing). Default settings were used for sequence filtering and
quality control. The missense mutation of the SeAx cell line was
identified in 100% of the sequences and had a total coverage of 81.
The nonsense mutation of the Hut-78 cell line was identified in
100% of the sequences and had a total coverage of 163. The
missense mutation of the Hut-78 cell line was identified in 97% of
the sequences and had a total coverage of 380.
siRNA transfection
Transfection was carried out using 4ml TurboFect in vitro Transfec-
tion Reagent (Fermentas, Burlington, Canada). A volume of 50nM p53
siRNA or scrambled siRNA from Dharmacon (Thermo Scientific,
Chicago, IL) was mixed with 200 ml GIBCO Opti-MEM I (Invitrogen)
and incubated for 20minutes before application to 500,000 cells per ml.
The efficiency and specificity of knockdown was documented at the
protein level by western blot analysis.
Flow cytometry analysis
Measurement of cell-cycle phase distribution and proliferation rate
was performed using BrdU/DNA analysis using the Cell Lab Quanta
SC MPL flow cytometer (Beckman Coulter, Fullerton, CA). Cells were
incubated with 10mM BrdU. Following cell fixation in ice-cold 70%
ethanol overnight, cells were incubated in 2M HCl for 30minutes,
washed in neutralizing buffer (0.2M Na2B4O7, pH 8.5), and resuspended
in dilution buffer (0.5% Tween-20 and 0.5% albumin bovine serum in
phosphate-buffered saline (PBS)) before the addition of anti-BrdU
mouse antibodies (Becton Dickinson, Franklin Lakes, NJ). Goat anti-
mouse antibodies labeled with Alexa-Fluor 488 (1:1,000; Invitrogen)
were applied as secondary antibodies. Subsequently, the DNA was
counterstained with 7-aminoactinomycin D (Becton Dickinson).
Cell viability was determined using propidium iodide (5mgml–1)
exclusion assay and flow cytometry analysis. Apoptosis was deter-
mined by flow cytometry using the FITC-annexin V/propidium iodide
protocol of the manufacturer (Beckman Coulter) as previously
described (Kamstrup et al., 2010b).
Cellular senescence assay
The SA-b-gal staining was performed as a marker of cellular sen-
escence. The cells were exposed to nutlin-3a for 72 hours and then
placed on glass slides by cytospin centrifugation at 13,000 r.p.m. for
8minutes. Following two washings in PBS (pH 7), samples were
fixed in 0.5% glutaraldehyde in PBS (pH 7) for 15minutes, washed
twice with 20ml 1mM MgCl2 in PBS (pH 6), and stained with the SA-
b-gal staining solution containing 1mgml–1 of 5-bromo-4-chloro-3-
indolyl b-galactopyranocid (0.04ml dimethylformamide per ml),
0.0012mM potassium ferrocyanide, and 1mM MgCl2 in PBS (pH 6)
overnight at 37 1C. Cells were considered positive when the
cytoplasm was stained with SA-b-gal.
Cell extracts and western blotting
Whole-cell extracts were prepared as described previously
(Kamstrup et al., 2010b). Equal amounts of protein were separated
by 12% Bis-Tris gel electrophoresis at 200V, followed by electro-
phoretic transfer to a nitrocellulose membrane (Bio-Rad Laboratories,
Hercules, CA). p53, MDM2, and p21 from Cell Signalling (Beverly,
MA) and anti-b-actin antibody from Sigma-Aldrich were used.
Immunoreactivity was detected and quantified with the infrared
Odyssey Imaging System (Li-Cor, Lincoln, NE).
Statistics
Continuous data are reported as means with SD. The differences
were evaluated using Student’s t-test. Statistical analysis was
performed using GraphPad Prism Version 4.03 (GraphPad Software,
San Diego, CA) or Excel (Microsoft, Redmond, WA). A P-value of
o0.05 was considered significant.
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